title: Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
authors.affiliation: University of California, Los Angeles, CA, USA. defurst@mednet.ucla.edu
authors.forename: D E
authors.initials: DE
authors.lastname: Furst
authors.forename: F C
authors.initials: FC
authors.lastname: Breedveld
authors.forename: J R
authors.initials: JR
authors.lastname: Kalden
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
authors.forename: C E
authors.initials: CE
authors.lastname: Antoni
authors.forename: J W J
authors.initials: JW
authors.lastname: Bijlsma
authors.forename: G R
authors.initials: GR
authors.lastname: Burmester
authors.forename: B
authors.initials: B
authors.lastname: Cronstein
authors.forename: E C
authors.initials: EC
authors.lastname: Keystone
authors.forename: A
authors.initials: A
authors.lastname: Kavanaugh
authors.forename: L
authors.initials: L
authors.lastname: Klareskog
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000628:therapy; D006801:Humans; D007376:Interleukin-2 / Q000037:antagonists & inhibitors; D012216:Rheumatic Diseases / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha